{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:48:07Z","timestamp":1791204487077,"version":"4.2.0"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The purpose of this study was to assess the antiviral activity of the rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate combination and to describe the pharmacokinetics of rilpivirine and its association with resistance in clinical routine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective multicentre cohort study was performed in both naive and pretreated HIV patients receiving the once\u2010daily rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate regimen. Immuno\u2010virologic and resistance data, and rilpivirine plasma trough concentrations were collected over the follow\u2010up. Statistical analyses were performed to evaluate the relationship between rilpivirine pharmacokinetics and virological response. Receiver operating characteristic (ROC) curve analysis was performed to determine the best target rilpivirine trough concentration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 379 patients were included. After a median follow\u2010up of 28 months, 26% of patients discontinued mainly due to toxicity and the virological success rate was 65.7%. Virological failure occurred in 5% of patients. A significant proportion of patients with HIV\u2010RNA &gt; 40 copies\/mL displayed rilpivirine plasma trough concentrations below the currently used 50 ng\/mL efficacy threshold at both M6 (28%) and M12 (31%), in agreement with a significant lower median rilpivirine plasma trough concentration compared with patients virologically suppressed. Half of the patients with virologic failure who acquired rilpivirine resistance mutations had at least one suboptimal rilpivirine trough concentration. The optimal target for rilpivirine trough concentration was 70 ng\/mL (sensitivity 75.4%; specificity 61.5%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study shows the impact of rilpivirine plasma trough concentration on both virological response and the emergence of rilpivirine mutations. Moreover, our results suggest that a higher target of rilpivirine trough concentration could be proposed in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14344","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T11:54:38Z","timestamp":1588766078000},"page":"2404-2413","source":"Crossref","is-referenced-by-count":13,"title":["Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV\u2010infected patients"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9193-1120","authenticated-orcid":false,"given":"Nad\u00e8ge","family":"N\u00e9ant","sequence":"first","affiliation":[{"name":"Laboratoire de Pharmacocin\u00e9tique et Toxicologie Aix Marseille Univ, APHM, INSERM, CNRS, CRCM SMARTc, H\u00f4pital La Timone  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-8288","authenticated-orcid":false,"given":"Minh Patrick","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Bichat\u2010Claude Bernard, Laboratoire de Pharmacologie\u2010Toxicologie, IAME, UMR 1137, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9 and INSERM  Paris F\u201075018 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-1399","authenticated-orcid":false,"given":"Na\u00efm","family":"Bouazza","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes  EA7323, Sorbonne Paris Cit\u00e9 France"},{"name":"Unit\u00e9 de Recherche Clinique Paris Descartes Necker Cochin, AP\u2010HP  France"},{"name":"CIC\u20101419 Inserm, Cochin\u2010Necker  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4944-8063","authenticated-orcid":false,"given":"Florence","family":"Gattacceca","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, INSERM, CNRS, CRCM SMARTc  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-1117","authenticated-orcid":false,"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Univ Paris Diderot, APHP, IAME\u2010UMR 1137, H\u00f4pital Bichat\u2010Claude Bernard, Service des Maladies Infectieuses et Tropicales  Paris F\u201075018 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-8082","authenticated-orcid":false,"given":"Catherine","family":"Dhiver","sequence":"additional","affiliation":[{"name":"IHU M\u00e9diterran\u00e9e Infection, Aix Marseille Univ., AP\u2010HM, URMITE UM 63 CNRS 7278 IRD 198 INSERM 1095  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bregigeon","sequence":"additional","affiliation":[{"name":"APHM, H\u00f4pital Sainte\u2010Marguerite Service d'Immuno\u2010h\u00e9matologie clinique  Marseille F\u201013009 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"IHU M\u00e9diterran\u00e9e Infection, Aix Marseille Univ., AP\u2010HM, URMITE UM 63 CNRS 7278 IRD 198 INSERM 1095  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Bichat\u2010Claude Bernard, Laboratoire de Pharmacologie\u2010Toxicologie, IAME, UMR 1137, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9 and INSERM  Paris F\u201075018 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1917-0777","authenticated-orcid":false,"given":"Catherine","family":"Tamalet","sequence":"additional","affiliation":[{"name":"IHU M\u00e9diterran\u00e9e Infection, Aix Marseille Univ., AP\u2010HM, URMITE UM 63 CNRS 7278 IRD 198 INSERM 1095  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-1525","authenticated-orcid":false,"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Bichat\u2010Claude Bernard, Laboratoire de Virologie, IAME, UMR 1137, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9 and INSERM  Paris F\u201075018 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-5851","authenticated-orcid":false,"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacocin\u00e9tique et Toxicologie Aix Marseille Univ, APHM, INSERM, CNRS, CRCM SMARTc, H\u00f4pital La Timone  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-9648","authenticated-orcid":false,"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, APHM, INSERM 1207, IRD 190, UVE, H\u00f4pital La Timone, Laboratoire de Pharmacocin\u00e9tique et Toxicologie  Marseille F\u201013005 France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"European Medicines Agency. (2011).Summary product of characteristics EVIPLERA.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002312\/WC500118802.pdf."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001677"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000911"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-216"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000087"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711209105"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1179\/1528433614Z.0000000009"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824d006e"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2405-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00899-16"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-760"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0183-8"},{"key":"e_1_2_9_16_1","unstructured":"BrochotA De La RosaG VisP et al.Generalised additive modelling of virologic response to the NNRTIs rilpivirine (rilpivirine TMC278) and efavirenz (EFV) in treatment\u2010naive HIV\u2010infected patients: pooled data from ECHO and THRIVE. In: Abstracts of the Thirteenth European AIDS Belgrade Serbia 2011. European AIDS Clinical Society Brussels Belgium Abstract PS12\/7."},{"key":"e_1_2_9_17_1","unstructured":"Rapport Morlat.Prise en charge m\u00e9dicale des personnes vivant avec le VIH recommandations du groupe d'experts rapport 2018. Annexe Pharmacologique 2018.https:\/\/cns.sante.fr\/wp-content\/uploads\/2018\/03\/experts-vih_pharmacologie.pdf"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S152090"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20037"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3188"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19812"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv018"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2579-2"},{"key":"e_1_2_9_24_1","unstructured":"World Medical Association. (2013).World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Last amended by the 64th WMA general assembly Brazil.https:\/\/www.wma.net\/wp-content\/uploads\/2016\/11\/DoH-Oct2013-JAMA.pdf"},{"key":"e_1_2_9_25_1","unstructured":"International conference on harmonization. (1996)ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1).https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181c05adf"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2016.1194528"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-13-S4-P186"},{"key":"e_1_2_9_29_1","unstructured":"Food and Drug Administration.2010.Center for drug evaluation and research (CDER) application number: 202022orig1s000.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202022Orig1s000MedR.pdf"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz141"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14344","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T06:11:20Z","timestamp":1693807880000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/bcp.14344"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14344","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}